Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

摘要

BackgroundCost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to generic drug introduction.